Soligenix Publishes Phase 2a Study Results for SGX945 in Behcet's Disease

Soligenix announced that the results from its Phase 2a proof of concept study evaluating SGX945, or dusquetide, in the treatment of Behcet's Disease have been published in Rheumatology (Oxford). The Phase 2a study, evaluating control of oral ulcers in Behcet's Disease, reported beneficial effects for 7 of 8 patients, over the 4 weeks of treatment as well as a potentially enduring effect through the 4 weeks of follow-up. Using the Phase 3 study of apremilast as a baseline for comparison, this open-label study indicated that the area under the curve, average number of oral ulcers, and improvements in oral pain for SGX945 were similar to outcomes obtained in the apremilast study. Notably, outcomes in weeks 5 through 8 continued to show similar outcomes, even though apremilast treatment was continued through this period whereas SGX945 treatment was stopped at Week 4, per study design. SGX945 was well-tolerated with no treatment-related adverse events. Common adverse events for apremilast included diarrhea - 41% of patients -, nausea - 19% of patients - and headache - 14% of patients -, none of which were observed with SGX945.